WallStSmart

Abbott Laboratories (ABT)vsViemed Healthcare Inc (VMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 16301% more annual revenue ($44.33B vs $270.28M). ABT leads profitability with a 14.7% profit margin vs 5.5%. VMD trades at a lower P/E of 24.8x. VMD earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

VMD

Buy

56

out of 100

Grade: C

Growth: 8.7Profit: 5.5Value: 8.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
VMDUndervalued (+51.2%)

Margin of Safety

+51.2%

Fair Value

$17.32

Current Price

$9.35

$7.97 discount

UndervaluedFair: $17.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

VMD3 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
25.5%8/10

Revenue surging 25.5% year-over-year

EPS GrowthGrowth
29.8%8/10

Earnings expanding 29.8% YoY

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VMD2 concerns · Avg: 3.0/10
Market CapQuality
$354.37M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : VMD

The strongest argument for VMD centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 25.5% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : VMD

The primary concerns for VMD are Market Cap, Profit Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while VMD is a growth play — different risk/reward profiles.

VMD carries more volatility with a beta of 1.23 — expect wider price swings.

VMD is growing revenue faster at 25.5% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

VMD scores higher overall (56/100 vs 51/100) and 25.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Viemed Healthcare Inc

HEALTHCARE · MEDICAL DEVICES · USA

Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.

Want to dig deeper into these stocks?